Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

[1]  M. Berger,et al.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[3]  E. Mardis,et al.  Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC) , 2016 .

[4]  J. Machiels,et al.  Window of opportunity studies: Do they fulfil our expectations? , 2016, Cancer treatment reviews.

[5]  Ash A. Alizadeh,et al.  Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq , 2015, Expert review of molecular diagnostics.

[6]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[7]  A. Bardia,et al.  500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2− advanced/metastatic breast cancer: results from a Phase Ib clinical trial , 2014 .

[8]  R. Finn,et al.  Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer , 2014 .

[9]  D. Juric,et al.  Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Miller,et al.  Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways , 2014, Pharmacogenomics and personalized medicine.

[11]  G. Shapiro,et al.  A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. , 2014 .

[12]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[13]  Didier Verhoeven,et al.  Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial , 2013, Journal of the National Cancer Institute.

[14]  G. Shapiro,et al.  Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. , 2013 .

[15]  W. Sellers,et al.  Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer. , 2013 .

[16]  Andrew C. Wood,et al.  Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma , 2013, Clinical Cancer Research.

[17]  Frederick A. Dick,et al.  Molecular mechanisms underlying RB protein function , 2013, Nature Reviews Molecular Cell Biology.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[19]  S. M. Rubin.  Deciphering the retinoblastoma protein phosphorylation code. , 2013, Trends in biochemical sciences.

[20]  Tao Wang,et al.  Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer , 2012, Clinical Cancer Research.

[21]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[22]  H. Kuerer,et al.  Circulating tumour cells in non-metastatic breast cancer: a prospective study. , 2012, The Lancet. Oncology.

[23]  P. Tonin,et al.  An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer , 2012, Oncogene.

[24]  Ben H. Park,et al.  Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.

[25]  R. Clarke,et al.  Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.

[26]  Jean Y. J. Wang,et al.  Targeting the RB-pathway in Cancer Therapy , 2010, Clinical Cancer Research.

[27]  Kingshuk Roy Choudhury,et al.  A Robust Automated Measure of Average Antibody Staining in Immunohistochemistry Images , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  R. Greil,et al.  Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Gao Hai-feng,et al.  Proliferation marker Ki-67 in early breast cancer , 2009 .

[30]  B. Calvo,et al.  Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Dowsett,et al.  A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Mitch Dowsett,et al.  Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. , 2007, Journal of the National Cancer Institute.

[33]  M. Barbacid,et al.  Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.

[34]  J. Bartek,et al.  checkpoint . D-cyclin-dependent kinase-pRb-controlled G 1 from diverse classes of receptors at the cyclin Convergence of mitogenic signalling cascades , 1996 .